[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

FirstWord: Market Research Reports

FirstWord is a major healthcare intelligence provider worldwide. The customers are offered upscale reports on various sectors of pharmaceutical industry. Research is carried out by best specialists in pharma market who ensure the clients with unique data, deep insight into the issue, latest events and new technologies.

The experts have access to reliable and abounding data resources to perform qualitative and extensive pharma reports. The area under study involves: biosimilars, medications, orphan drugs, patient-centric disease treatment and healthcare technologies.

In the reports customers will find basic market information on the products and the following takeaways:

  • Leading and emerging trends;
  • Medical enterprises;
  • Critical analysis for best strategies;
  • Multichannel marketing modelling to guide the customers to the right channels and content;
  • Key success factors and opportunities for pharma industry;
  • Pharma sales analysis; etc.


FirstWord helps you stay competitive, get 5 year forecast and improve productive efficiency. To acquire measurable and sufficient outcome it is vital to use FirstWord consulting service.

Publications found: 700
Sort by:

REMS: A Standardized Approach to Risk Management

US$ 395.00

Risk Evaluation and Mitigation Strategies. Until recently, the Federal Drug Administration’s REMS program impacted drugs that would not have been otherwise approved due to their risks. The hurdles, co...

September 2010 42 pages

Pharmaceutical Market Access in Latin America

US$ 395.00

With its top eight markets valued at more than $30 billion in 2009, Latin America represents shining hope for an industry in flux. Strong, steady growth, resiliency in the face of global downturn, pos...

August 2010 58 pages

Pay-for-Delay: An Unsettled Future Lies Ahead

US$ 395.00

Anti-competitive or just good business?That’s the question facing the pharmaceutical industry and regulators alike, as companies dealing with drugs going off-patent increasingly rely on pay-for-delay...

July 2010 36 pages

Branded vs Generic Drugs in Russia and CEE – Expert Insights

US$ 395.00

Across Russia and former Communist countries in Central and Eastern Europe, the battle for market share is being played out on three fronts between patented drugs, branded and commodity generics. And...

July 2010 43 pages

Drug Brand Perceptions: Breast Cancer – a Social Media Analysis

US$ 395.00

Over the past decade, the pharmaceutical industry has built up its social media presence. From Facebook pages and Twitter micro-blogs to branded community forums and supported web pages, drug companie...

July 2010 60 pages

Specialty Generics: Climbing the Value Chain

US$ 195.00

“Mighty things from small beginnings grow,” John Dryden once astutely noted. Although the influential 17th century poet and literary critic knew nothing of medicine and marketing, his words ring true...

June 2010 34 pages

Branded Generics: A Gateway to Emerging Markets

US$ 295.00

Around the globe, emerging markets are on the move. From Brazil, Russia and India to China, Turkey, Mexico and South Korea, experts predict emerging markets will represent 70 percent of industry growt...

June 2010 46 pages

Pharma Sales Forces: Mexico

US$ 295.00

Enchiladas, cerveza, sombreros and ponchos: Forget what you thought you knew about Mexico. With the 11th largest economy in the world and a pharmaceutical industry expected to hit $14.9 billion by 201...

June 2010 45 pages

Trends in Mobile Medicine: Smartphone Apps for Physicians

US$ 395.00

“Healing is a matter of time,” Hippocrates once said, “but it is sometimes also a matter of opportunity.”As smartphone technology rapidly evolves and puts knowledge literally into the hands of physici...

May 2010 66 pages

Pharma 2.0 -- De-Risking the Business Model

US$ 395.00

Adapt. Evolve. Survive. Darwinian Theory as a business model for the pharmaceutical industry? Never has it been more apt—or timely. As it enters one of its most challenging periods ever, the pharmaceu...

May 2010 44 pages

US Healthcare Reform: Impact and Implications for the Pharmaceutical and Biotech Industries

US$ 295.00

Millions of Americans protested it, conservative pundits howled in outrage and lobbyists worked feverishly behind closed doors to stop it. But in the end, on March 30, 2010, President Obama’s nascent...

May 2010 46 pages

The State of Merck & Co

US$ 295.00

New directions. New faces. Major new facilities. As 2009 ended and the curtain lifted on 2010, Merck & Co emerged from its $41.1 billion union with Schering-Plough with a whole new outlook. Starti...

April 2010 38 pages

The State of Roche

US$ 295.00

Expect the unexpected. For pharma giant Roche, those were words to live by as 2009 came to a close. Despite a strong showing in news analysis — of 179 articles published internationally on the compan...

April 2010 39 pages

The Life Cycle of Drug Brands: Concept to Market Share

US$ 395.00

The Life Cycle of Drug Brands: Concept to Market ShareThe match is on. The goal is in sight. Yet the rules of the game are shifting. For the $60 billion pharmaceutical marketing industry, keeping up w...

April 2010 55 pages

Leading Thoughts on Pharma & Social Media

US$ 295.00

Out of 430 million Facebook users, 60 million Twitter accounts and countless blogs, the cacophony of voices and opinions on the Internet is relentless. But that doesn’t mean the pharmaceutical industr...

March 2010 75 pages

The AstraZeneca Intelligence Dossier

US$ 295.00

One step forward, two steps back. At least that’s what the last two quarters of 2009 seemed like for pharmaceutical giant, AstraZeneca. Despite a strong showing in news analysis — of 221 articles publ...

March 2010 69 pages

The Johnson & Johnson Intelligence Dossier

US$ 295.00

May you live in interesting times—or so the old curse goes. Johnson & Johnson is certainly doing just that. After a year of upsets and some victories, J&J ended the last half of 2009 with the...

March 2010 35 pages

The Bristol-Myers Squibb Intelligence Dossier

US$ 295.00

“Without the strength to endure the crisis, one will not see the opportunity within,” author and business commentator Chin-Ning Chu recently said. “It is within the process of endurance that opportuni...

March 2010 51 pages

The Eli Lilly Intelligence Dossier

US$ 295.00

From the ashes of recent economic fires, a new leader is rising. Following one of the worst years ever for the pharmaceutical industry, in which economic downturn was compounded by regulatory crises,...

March 2010 46 pages

Digital Healthcare: EHRs, e-prescribing and Patient Driven Applications

US$ 395.00

From the finance industry to manufacturing, from customer service to on-line shopping, the internet has changed the way the world does business. And now it’s changing the way it takes care of its heal...

March 2010 59 pages

Creating Common Points of Reference: Expert Insight into Closed Loop Marketing

US$ 395.00

The sign on many physicians’ doors says it all: “The doctor no longer sees sales reps.” A growing trend amongst health care professionals (HCPs) frustrated by traditional marketing that, at times, sat...

March 2010 53 pages

Engaging with Physicians in an Era of Transparency

US$ 595.00

“It's no use going back to yesterday,” Alice said in Wonderland, “because I was a different person then.”As Alice’s environment changed her, so, too, is an era of “looking glass” transparency changing...

March 2010 51 pages

EU Central and Eastern European Pharma Markets - Secrets of Access and Engagement

US$ 395.00

Homogeneity and standardization—across the European Union, they’re the bricks for building an economic powerhouse that offers a single system of laws governing people, goods, services and capital. Yet...

March 2010 44 pages

Branded vs Generics Drugs in Latin America

US$ 395.00

On every border, across every frontier of Latin America, a revolution is underway. Prefaced by the ground-breaking Hatch-Waxman Act of 1984, the war for market share between generic and branded pharma...

February 2010 52 pages

Mapping the e-Pharma Landscape -- Who's Doing What in Pharma Social Media

US$ 295.00

More than 430 million people talk on Facebook. Another 60 million people tweet on Twitter. Millions more chatter on YouTube, MySpace, Windows Life and instant messaging. In short, the universe of soci...

February 2010 88 pages

Reaching the Empowered Patient -- Opportunities and Challenges in DTC Marketing

US$ 395.00

Direct marketing restrictions are everywhere. Consumers are suspicious. Physicians are shutting their doors to reps and the market is changing. Bottom line: Lackluster profits across the industry. But...

February 2010 53 pages

KOL Management - The New Rules

US$ 395.00

“When the going gets tough,” Joseph P. Kennedy once said, “the tough get going…” And when it comes to the beleaguered pharmaceutical industry, he could have added, “… then they rethink how they do bus...

January 2010 33 pages

The CME Landscape - Change and Challenges

US$ 395.00

“The future influences the present just as much as the past.” ~ (Friedrich Nietzsche, scholar and philosopher)When it comes to the past, present and future of the continuing medical education (CME) in...

January 2010 36 pages

Healthcare Stakeholders in Latin America - Secrets of Engagement

US$ 395.00

Twenty countriesThree languagesSeven racial groupsAnd an estimated population of 623 million people by 2030By anyone’s measure, Latin America is one of the most ethnically diverse and economically com...

December 2009 32 pages

Pharma & Social Media -- Report Collection

US$ 975.00

1.7 billion users More than 380 per cent growth since 2000 Nearly 75 per cent penetration in North America alone1 The fastest growing, most complex, yet easiest-to-access...

November 2009 161 pages

Conference Intelligence Dossier: ACR/ARHP Annual Meeting 2009

US$ 995.00

Their impact is undeniable, the burden of disease unfathomable. More than 100 musculoskeletal and rheumatic diseases currently plague North America, with the number of sufferers growing daily.The stat...

November 2009 44 pages

The Roche Intelligence Dossier

US$ 295.00

As the fourth largest pharmaceutical company in the world, with annual revenues of $43.9 billion, some of the most instantly recognisable drugs marketed and the kind of pipeline smaller companies only...

November 2009 48 pages

The GSK Intelligence Dossier

US$ 295.00

After two anemic years, GSK is ready to breathe new life.Despite intense competition from generics in the US, the company has finally reported a healthy growth in the third quarter of 2009.Now, eager...

November 2009 53 pages

The Novartis Intelligence Dossier

US$ 295.00

International censure over Novartis’ grave delays in supplying the H1N1 vaccine.Renewed criticism by an institutional investor for CEO Daniel Vasella’s substantial pay package and considerable power.A...

November 2009 55 pages

The Value of a Good Reputation in Pharma

US$ 795.00

“It takes many good deeds to build a good reputation,” Benjamin Franklin once wisely observed, “and only one bad one to lose it.”How many good deeds will it take to repair the pharmaceutical industry’...

November 2009 40 pages

Pharma, Patients and Social Media: Engaging the Empowered Consumer

US$ 295.00

Its scope is global, its membership limitless, and its power undeniable.Social media — whether Facebook, Twitter, viral messages or blogs — has gripped the public imagination, created its own language...

October 2009 38 pages

Conference Intelligence Dossier: ECCO 15 - ESMO 34 Congress, 2009

US$ 995.00

Every year, the numbers grow exponentially: 10.9 million new cancer diagnoses worldwide, 6.7 million cancer deaths annually.But as the number of cases expand, so, too, does the number of five-year sur...

October 2009 78 pages

Conference Intelligence Dossier: EASD Annual Meeting 2009

US$ 995.00

The numbers are staggering: More than 200 million people around the world now suffer from diabetes and its major complications. According to the World Health Organization, that figure is expected to s...

October 2009 90 pages

The Pfizer Intelligence Dossier

US$ 295.00

In boardrooms, around water coolers and behind closed office doors, decision-makers in the pharmaceutical industry are asking questions: What’s happening with Pfizer? What developments have occurred i...

October 2009 60 pages

Pharma Sales Forces: Change in the Face of Adversity

US$ 395.00

“Change,” futurist Alvin Toffler once said, “is the process by which the future invades our lives.” For the pharmaceutical sales industry, that future is unfolding now. Dropping revenue, increasingly...

October 2009 40 pages

Pharma, Physicians and Social Media: Engaging Opportunities and Challenges

US$ 495.00

The inexorable rise of social media is resulting in more and more business communities taking notice of its huge global potential, and the pharmaceutical industry is no exception.Whilst patients have...

September 2009 50 pages

Conference Intelligence Dossier: ESC 2009 Congress, Barcelona

US$ 595.00

Medical Meeting Outcomes and Insights Barcelona, September 2009 – The results of three drug trials announced at the prestigious European Society of Cardiology Congress 2009 are expected to have a maj...

September 2009

Pharma Corporate Venture Capital (CVC): Key Players, New Conditions and Big Opportunities

US$ 495.00

A good opportunity is opening up for pharma CVCs, but only if the corporate structure is right The medical/health and life science sector was the second highest corporate venture capital (CVC) invest...

September 2009 46 pages

Pharma and Social Media -- the Leaders and Followers

US$ 295.00

The phenomenon of social media is seeing the creation of information and interest communities on an unparalled scale, and health is among the most popular.For pharmaceutical companies, the potential b...

August 2009 75 pages

Merck & Co and Schering-Plough: a Marriage of Convenience?

US$ 495.00

The prospects for a major new company The pharmaceutical industry’s appetite for major mergers seems unabated, and the $41.1 billion Merck & Co/Schering-Plough deal - one of the largest ever merg...

August 2009 50 pages

Roche & Genentech: a Model for Future Biotech Deals?

US$ 295.00

Could this single deal mark a phase of big pharma/biotech consolidation? In March 2009, after months of negotiations, Roche acquired the 44 percent of shares that it did not already own in its long-t...

August 2009 42 pages

BMS & Medarex: a Valuable Partnership?

US$ 295.00

A positive move, but not one which deals with Bristol-Myers Squibb’s upcoming patent expiry problems On July 22, 2009, Bristol-Myers Squibb announced that it would acquire – at a considerable premium...

August 2009

ASCO 2009: Significant Developments in Context

US$ 995.00

The recent ASCO meeting was attended by around 30,000 cancer researchers and physicians and over 4,000 abstracts covering a wide range of clinical trial results and related topics were presented. How...

July 2009 175 pages

Johnson & Johnson: Positioning for Market Leadership?

US$ 295.00

How does the world's 7th largest pharma company plan to grow its pharmaceutical revenues? For competitors and investors alike this is a key question, and one that must be considered in the light of t...

July 2009

Branded Generics: Strategies and Tactics for Winning in Latin America

US$ 1,995.00

... …but in Mexico it’s the small companies that have done well in generics.” Xavier Tello, Independent healthcare industry expert “As a manufacturer, you should ... in hospital-driven niches, such as oncology Branded Generics: Strategies and Tactics for Winning in Latin America answers key questions: Who are ...

March 2009 71 pages

Filters

Search

Categories

1
43
3
2
3
2
1
16
1
1
8
2
4
1
19
1
1
1
2
31
6
24
62
10
455

Publishers

700

Regions

2
1
15
1
1
14
4
1
660
1

Price

Date

Pages

Offers